Browsing by Subject "Isocitrate Dehydrogenase"
Now showing items 1-9 of 9
-
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
(Cancer research, 2013-01)Point mutations at Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the "oncometabolite" D-2-hydroxyglutarate (D-2HG). ... -
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
(Oncotarget, 2012-07)Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most common type of primary malignant ... -
IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
(Biochemical and biophysical research communications, 2010-07-13)Isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are enzymes which convert isocitrate to alpha-ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+to NADPH). IDH1/2 were ... -
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
(Current opinion in neurology, 2011-12)Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to α-ketoglutarate (α-KG) and reduce NADP to NADPH. Point mutations of IDH1 and IDH2 have been discovered in gliomas. IDH mutations cause loss of native ... -
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
(Oncotarget, 2012-08)Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. ... -
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
(Oncotarget, 2014-03-30)Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which ... -
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
(Eur J Med Chem, 2016-08-25)INTRODUCTION: Malignant gliomas frequently harbor mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Studies suggest that IDH mutation contributes to tumor pathogenesis through mechanisms that are mediated by the neomorphic ... -
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
(Nature, 2012-02-15)The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating ... -
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
(Cell research, 2019-06)Although targeted therapies have proven effective and even curative in human leukaemia, resistance often ensues. IDH enzymes are mutated in ~20% of human AML, with targeted therapies under clinical evaluation. We ...
